About: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.77 (-3.00%)
XLO NASDAQ Xilio Development Inc
Xilio Development Inc share price
Atividade de preço de XLO
Último preço
$ 8,140
Variação (24h)
0,13 USD (1,62%)
Volume
11.38K
Volume (média 4 sem.)
-
Abertura
$ 7,81
Variação do dia
$ 7,57 - $ 8,14
Fechamento anterior
$ 8,01
Último negócio
28 Oct, 6:23 pm GMT+0
Atrasado
28 Oct, 6:23 pm GMT+0
XLO price performance
Atrasado
28 Oct, 6:23 pm GMT+0
quote.marketSignals